Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 243

1.

Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease.

Klasić M, Markulin D, Vojta A, Samaržija I, Biruš I, Dobrinić P, Ventham NT, Trbojević-Akmačić I, Šimurina M, Štambuk J, Razdorov G, Kennedy NA, Satsangi J, Dias AM, Pinho S, Annese V, Latiano A, D'Inca R; IBD consortium, Lauc G, Zoldoš V.

Clin Epigenetics. 2018 Jun 4;10:75. doi: 10.1186/s13148-018-0507-y. eCollection 2018.

2.

Mutational analysis identifies therapeutic biomarkers in inflammatory bowel disease-associated colorectal cancers.

Din S, Wong K, Müller MF, Oniscu A, Hewinson J, Black CJ, Miller ML, Jiménez-Sánchez A, Rabbie R, Rashid M, Satsangi J, Adams DJ, Arends MJ.

Clin Cancer Res. 2018 Jun 27. pii: clincanres.3713.2017. doi: 10.1158/1078-0432.CCR-17-3713. [Epub ahead of print]

PMID:
29950348
3.

Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.

D'Haens G, Reinisch W, Panaccione R, Satsangi J, Petersson J, Bereswill M, Arikan D, Perotti E, Robinson AM, Kalabic J, Alperovich G, Thakkar R, Loftus EV.

Am J Gastroenterol. 2018 Jun;113(6):872-882. doi: 10.1038/s41395-018-0098-4. Epub 2018 Jun 5.

PMID:
29867173
4.

Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes from the European Society for Blood and Marrow Transplantation.

Brierley CK, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J, Onida F, Cassinotti A, Satsangi J, Kazmi M, López-Sanromán A, Schmidt C, Farge D, Travis SPL, Hawkey CJ, Snowden JA; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP).

J Crohns Colitis. 2018 May 18. doi: 10.1093/ecco-jcc/jjy069. [Epub ahead of print]

PMID:
29788233
5.

Purine metabolism controls innate lymphoid cell function and protects against intestinal injury.

Crittenden S, Cheyne A, Adams A, Forster T, Robb CT, Felton J, Ho GT, Ruckerl D, Rossi AG, Anderton SM, Ghazal P, Satsangi J, Howie SE, Yao C.

Immunol Cell Biol. 2018 May 14. doi: 10.1111/imcb.12167. [Epub ahead of print]

PMID:
29758102
6.

Mitochondrial DNA Is a Pro-Inflammatory Damage-Associated Molecular Pattern Released During Active IBD.

Boyapati RK, Dorward DA, Tamborska A, Kalla R, Ventham NT, Doherty MK, Whitfield PD, Gray M, Loane J, Rossi AG, Satsangi J, Ho GT.

Inflamm Bowel Dis. 2018 May 1. doi: 10.1093/ibd/izy095. [Epub ahead of print]

PMID:
29718255
7.

Top-down in the Long Term in Crohn's Disease.

Boyapati RK, Ho GT, Satsangi J.

J Crohns Colitis. 2018 Apr 27;12(5):513-514. doi: 10.1093/ecco-jcc/jjy027. No abstract available.

PMID:
29548025
8.

Shared activity patterns arising at genetic susceptibility loci reveal underlying genomic and cellular architecture of human disease.

Baillie JK, Bretherick A, Haley CS, Clohisey S, Gray A, Neyton LPA, Barrett J, Stahl EA, Tenesa A, Andersson R, Brown JB, Faulkner GJ, Lizio M, Schaefer U, Daub C, Itoh M, Kondo N, Lassmann T, Kawai J; IIBDGC Consortium, Mole D, Bajic VB, Heutink P, Rehli M, Kawaji H, Sandelin A, Suzuki H, Satsangi J, Wells CA, Hacohen N, Freeman TC, Hayashizaki Y, Carninci P, Forrest ARR, Hume DA.

PLoS Comput Biol. 2018 Mar 1;14(3):e1005934. doi: 10.1371/journal.pcbi.1005934. eCollection 2018 Mar.

9.

Editorial: the influence of genetic factors in mediating the effects of tobacco smoke in IBD.

Adams A, Kalla R, Satsangi J.

Aliment Pharmacol Ther. 2018 Jan;47(2):306-307. doi: 10.1111/apt.14434. No abstract available.

PMID:
29265462
10.
11.

Fine-mapping inflammatory bowel disease loci to single-variant resolution.

Huang H, Fang M, Jostins L, Umićević Mirkov M, Boucher G, Anderson CA, Andersen V, Cleynen I, Cortes A, Crins F, D'Amato M, Deffontaine V, Dmitrieva J, Docampo E, Elansary M, Farh KK, Franke A, Gori AS, Goyette P, Halfvarson J, Haritunians T, Knight J, Lawrance IC, Lees CW, Louis E, Mariman R, Meuwissen T, Mni M, Momozawa Y, Parkes M, Spain SL, Théâtre E, Trynka G, Satsangi J, van Sommeren S, Vermeire S, Xavier RJ; International Inflammatory Bowel Disease Genetics Consortium, Weersma RK, Duerr RH, Mathew CG, Rioux JD, McGovern DPB, Cho JH, Georges M, Daly MJ, Barrett JC.

Nature. 2017 Jul 13;547(7662):173-178. doi: 10.1038/nature22969. Epub 2017 Jun 28.

12.

Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial.

Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J, Farge D, Hawkey CJ; ASTIC trial group; European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party; European Crohn's and Colitis Organisation.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):399-406. doi: 10.1016/S2468-1253(17)30056-0. Epub 2017 Apr 6.

13.

Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.

Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, Travis S, Morris J, Hamlin J, Dhar A, Nwokolo C, Edwards C, Creed T, Bloom S, Yousif M, Thomas L, Campbell S, Lewis SJ, Sebastian S, Sen S, Lal S, Hawkey C, Murray C, Cummings F, Goh J, Lindsay JO, Arebi N, Potts L, McKinley AJ, Thomson JM, Todd JA, Collie M, Dunlop MG, Mowat A, Gaya DR, Winter J, Naismith GD, Ennis H, Keerie C, Lewis S, Prescott RJ, Kennedy NA, Satsangi J; TOPPIC Study Group.

Lancet Gastroenterol Hepatol. 2016 Dec;1(4):273-282. doi: 10.1016/S2468-1253(16)30078-4. Epub 2016 Aug 30.

14.

A plea for TDM-based optimisation for treatment of Crohn's disease - Authors' reply.

Kennedy NA, Keerie C, Mowat C, Satsangi J.

Lancet Gastroenterol Hepatol. 2017 Feb;2(2):81-82. doi: 10.1016/S2468-1253(16)30222-9. Epub 2017 Jan 12. No abstract available.

PMID:
28403991
15.

MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation.

Ho GT, Aird RE, Liu B, Boyapati RK, Kennedy NA, Dorward DA, Noble CL, Shimizu T, Carter RN, Chew ETS, Morton NM, Rossi AG, Sartor RB, Iredale JP, Satsangi J.

Mucosal Immunol. 2018 Jan;11(1):120-130. doi: 10.1038/mi.2017.31. Epub 2017 Apr 12.

16.

Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease.

Lee JC, Biasci D, Roberts R, Gearry RB, Mansfield JC, Ahmad T, Prescott NJ, Satsangi J, Wilson DC, Jostins L, Anderson CA; UK IBD Genetics Consortium, Traherne JA, Lyons PA, Parkes M, Smith KG.

Nat Genet. 2017 Feb;49(2):262-268. doi: 10.1038/ng.3755. Epub 2017 Jan 9.

17.

Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7.

Luo Y, de Lange KM, Jostins L, Moutsianas L, Randall J, Kennedy NA, Lamb CA, McCarthy S, Ahmad T, Edwards C, Serra EG, Hart A, Hawkey C, Mansfield JC, Mowat C, Newman WG, Nichols S, Pollard M, Satsangi J, Simmons A, Tremelling M, Uhlig H, Wilson DC, Lee JC, Prescott NJ, Lees CW, Mathew CG, Parkes M, Barrett JC, Anderson CA.

Nat Genet. 2017 Feb;49(2):186-192. doi: 10.1038/ng.3761. Epub 2017 Jan 9.

18.

Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.

de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, Jostins L, Rice DL, Gutierrez-Achury J, Ji SG, Heap G, Nimmo ER, Edwards C, Henderson P, Mowat C, Sanderson J, Satsangi J, Simmons A, Wilson DC, Tremelling M, Hart A, Mathew CG, Newman WG, Parkes M, Lees CW, Uhlig H, Hawkey C, Prescott NJ, Ahmad T, Mansfield JC, Anderson CA, Barrett JC.

Nat Genet. 2017 Feb;49(2):256-261. doi: 10.1038/ng.3760. Epub 2017 Jan 9.

19.

Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease.

Ventham NT, Kennedy NA, Adams AT, Kalla R, Heath S, O'Leary KR, Drummond H; IBD BIOM consortium; IBD CHARACTER consortium, Wilson DC, Gut IG, Nimmo ER, Satsangi J.

Nat Commun. 2016 Nov 25;7:13507. doi: 10.1038/ncomms13507.

20.

Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies?

Boyapati RK, Ho GT, Satsangi J.

Clin Gastroenterol Hepatol. 2017 Jan;15(1):76-78. doi: 10.1016/j.cgh.2016.09.152. Epub 2016 Oct 5. No abstract available.

PMID:
27720912

Supplemental Content

Loading ...
Support Center